{"id":"https://openalex.org/W2245229130","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.636","title":"Evaluation of vinorelbine (N) and trastuzumab (H) as first-line therapy for patients (pts) with HER2- positive metastatic breast cancer (HER2+ MBC): Impact on clinical response and cardiac function","display_name":"Evaluation of vinorelbine (N) and trastuzumab (H) as first-line therapy for patients (pts) with HER2- positive metastatic breast cancer (HER2+ MBC): Impact on clinical response and cardiac function","publication_year":2004,"publication_date":"2004-07-15","ids":{"openalex":"https://openalex.org/W2245229130","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.636","mag":"2245229130"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2004.22.14_suppl.636","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.636","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.14_suppl.636","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5082736690","display_name":"Vicente Guillem Porta","orcid":"https://orcid.org/0000-0001-6073-6798","observed_orcids":["https://orcid.org/0000-0001-6073-6798"]},"institutions":[{"id":"https://openalex.org/I2961216182","display_name":"Hospital Cl\u00ednico San Carlos","ror":"https://ror.org/04d0ybj29","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2961216182","https://openalex.org/I4210139293"]},{"id":"https://openalex.org/I4210103093","display_name":"Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda","ror":"https://ror.org/01fh9k283","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210103093"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"V. Guillem Porta","raw_affiliation_strings":["Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Clinico San Carlos, Madrid, Spain; Institut Catala de Oncologia, Hospitalet Llobregat, Spain; Tampere University Hospital, Pikonlinna, France; Centre Hospitalier de Jolimont, Haine Saint-Paul, Belgium; Institut de Recherche Pierre Fabre, Boulogne, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Clinico San Carlos, Madrid, Spain; Institut Catala de Oncologia, Hospitalet Llobregat, Spain; Tampere University Hospital, Pikonlinna, France; Centre Hospitalier de Jolimont, Haine Saint-Paul, Belgium; Institut de Recherche Pierre Fabre, Boulogne, France","institution_ids":["https://openalex.org/I2961216182","https://openalex.org/I4210103093"]}]},{"author_position":"middle","author":{"id":null,"display_name":"M. Martin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2961216182","display_name":"Hospital Cl\u00ednico San Carlos","ror":"https://ror.org/04d0ybj29","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2961216182","https://openalex.org/I4210139293"]},{"id":"https://openalex.org/I4210103093","display_name":"Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda","ror":"https://ror.org/01fh9k283","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210103093"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"M. Martin","raw_affiliation_strings":["Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Clinico San Carlos, Madrid, Spain; Institut Catala de Oncologia, Hospitalet Llobregat, Spain; Tampere University Hospital, Pikonlinna, France; Centre Hospitalier de Jolimont, Haine Saint-Paul, Belgium; Institut de Recherche Pierre Fabre, Boulogne, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Clinico San Carlos, Madrid, Spain; Institut Catala de Oncologia, Hospitalet Llobregat, Spain; Tampere University Hospital, Pikonlinna, France; Centre Hospitalier de Jolimont, Haine Saint-Paul, Belgium; Institut de Recherche Pierre Fabre, Boulogne, France","institution_ids":["https://openalex.org/I2961216182","https://openalex.org/I4210103093"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112514720","display_name":"Miguel Gil Gil","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2961216182","display_name":"Hospital Cl\u00ednico San Carlos","ror":"https://ror.org/04d0ybj29","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2961216182","https://openalex.org/I4210139293"]},{"id":"https://openalex.org/I4210103093","display_name":"Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda","ror":"https://ror.org/01fh9k283","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210103093"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"M. Gil Gil","raw_affiliation_strings":["Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Clinico San Carlos, Madrid, Spain; Institut Catala de Oncologia, Hospitalet Llobregat, Spain; Tampere University Hospital, Pikonlinna, France; Centre Hospitalier de Jolimont, Haine Saint-Paul, Belgium; Institut de Recherche Pierre Fabre, Boulogne, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Clinico San Carlos, Madrid, Spain; Institut Catala de Oncologia, Hospitalet Llobregat, Spain; Tampere University Hospital, Pikonlinna, France; Centre Hospitalier de Jolimont, Haine Saint-Paul, Belgium; Institut de Recherche Pierre Fabre, Boulogne, France","institution_ids":["https://openalex.org/I2961216182","https://openalex.org/I4210103093"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076495612","display_name":"P. Kellokumpu-Lehtinen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2961216182","display_name":"Hospital Cl\u00ednico San Carlos","ror":"https://ror.org/04d0ybj29","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2961216182","https://openalex.org/I4210139293"]},{"id":"https://openalex.org/I4210103093","display_name":"Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda","ror":"https://ror.org/01fh9k283","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210103093"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"P. Kellokumpu-Lehtinen","raw_affiliation_strings":["Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Clinico San Carlos, Madrid, Spain; Institut Catala de Oncologia, Hospitalet Llobregat, Spain; Tampere University Hospital, Pikonlinna, France; Centre Hospitalier de Jolimont, Haine Saint-Paul, Belgium; Institut de Recherche Pierre Fabre, Boulogne, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Clinico San Carlos, Madrid, Spain; Institut Catala de Oncologia, Hospitalet Llobregat, Spain; Tampere University Hospital, Pikonlinna, France; Centre Hospitalier de Jolimont, Haine Saint-Paul, Belgium; Institut de Recherche Pierre Fabre, Boulogne, France","institution_ids":["https://openalex.org/I2961216182","https://openalex.org/I4210103093"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008752155","display_name":"Fran\u00e7oise Majois","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2961216182","display_name":"Hospital Cl\u00ednico San Carlos","ror":"https://ror.org/04d0ybj29","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2961216182","https://openalex.org/I4210139293"]},{"id":"https://openalex.org/I4210103093","display_name":"Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda","ror":"https://ror.org/01fh9k283","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210103093"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"F. Majois","raw_affiliation_strings":["Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Clinico San Carlos, Madrid, Spain; Institut Catala de Oncologia, Hospitalet Llobregat, Spain; Tampere University Hospital, Pikonlinna, France; Centre Hospitalier de Jolimont, Haine Saint-Paul, Belgium; Institut de Recherche Pierre Fabre, Boulogne, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Clinico San Carlos, Madrid, Spain; Institut Catala de Oncologia, Hospitalet Llobregat, Spain; Tampere University Hospital, Pikonlinna, France; Centre Hospitalier de Jolimont, Haine Saint-Paul, Belgium; Institut de Recherche Pierre Fabre, Boulogne, France","institution_ids":["https://openalex.org/I2961216182","https://openalex.org/I4210103093"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108554953","display_name":"Jamal Gasmi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2961216182","display_name":"Hospital Cl\u00ednico San Carlos","ror":"https://ror.org/04d0ybj29","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2961216182","https://openalex.org/I4210139293"]},{"id":"https://openalex.org/I4210103093","display_name":"Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda","ror":"https://ror.org/01fh9k283","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210103093"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"J. Gasmi","raw_affiliation_strings":["Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Clinico San Carlos, Madrid, Spain; Institut Catala de Oncologia, Hospitalet Llobregat, Spain; Tampere University Hospital, Pikonlinna, France; Centre Hospitalier de Jolimont, Haine Saint-Paul, Belgium; Institut de Recherche Pierre Fabre, Boulogne, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Clinico San Carlos, Madrid, Spain; Institut Catala de Oncologia, Hospitalet Llobregat, Spain; Tampere University Hospital, Pikonlinna, France; Centre Hospitalier de Jolimont, Haine Saint-Paul, Belgium; Institut de Recherche Pierre Fabre, Boulogne, France","institution_ids":["https://openalex.org/I2961216182","https://openalex.org/I4210103093"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025675769","display_name":"Delphine Aubert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2961216182","display_name":"Hospital Cl\u00ednico San Carlos","ror":"https://ror.org/04d0ybj29","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2961216182","https://openalex.org/I4210139293"]},{"id":"https://openalex.org/I4210103093","display_name":"Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda","ror":"https://ror.org/01fh9k283","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210103093"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"D. Aubert","raw_affiliation_strings":["Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Clinico San Carlos, Madrid, Spain; Institut Catala de Oncologia, Hospitalet Llobregat, Spain; Tampere University Hospital, Pikonlinna, France; Centre Hospitalier de Jolimont, Haine Saint-Paul, Belgium; Institut de Recherche Pierre Fabre, Boulogne, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Clinico San Carlos, Madrid, Spain; Institut Catala de Oncologia, Hospitalet Llobregat, Spain; Tampere University Hospital, Pikonlinna, France; Centre Hospitalier de Jolimont, Haine Saint-Paul, Belgium; Institut de Recherche Pierre Fabre, Boulogne, France","institution_ids":["https://openalex.org/I2961216182","https://openalex.org/I4210103093"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5077774407","display_name":"O. Bourrillon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2961216182","display_name":"Hospital Cl\u00ednico San Carlos","ror":"https://ror.org/04d0ybj29","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2961216182","https://openalex.org/I4210139293"]},{"id":"https://openalex.org/I4210103093","display_name":"Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda","ror":"https://ror.org/01fh9k283","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210103093"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"O. Bourrillon","raw_affiliation_strings":["Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Clinico San Carlos, Madrid, Spain; Institut Catala de Oncologia, Hospitalet Llobregat, Spain; Tampere University Hospital, Pikonlinna, France; Centre Hospitalier de Jolimont, Haine Saint-Paul, Belgium; Institut de Recherche Pierre Fabre, Boulogne, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Clinico San Carlos, Madrid, Spain; Institut Catala de Oncologia, Hospitalet Llobregat, Spain; Tampere University Hospital, Pikonlinna, France; Centre Hospitalier de Jolimont, Haine Saint-Paul, Belgium; Institut de Recherche Pierre Fabre, Boulogne, France","institution_ids":["https://openalex.org/I2961216182","https://openalex.org/I4210103093"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"22","issue":"14_suppl","first_page":"636","last_page":"636"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.8429999947547913},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9990000128746033},{"id":"https://openalex.org/keywords/vinorelbine","display_name":"vinorelbine","score":0.9620000123977661},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":1.0},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.8299999833106995},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.9890000224113464},{"id":"https://openalex.org/keywords/left-ventricular-ejection-fraction","display_name":"left ventricular ejection fraction","score":0.906000018119812},{"id":"https://openalex.org/keywords/cardiotoxicity","display_name":"cardiotoxicity","score":0.8949999809265137},{"id":"https://openalex.org/keywords/cardiac-function","display_name":"cardiac function","score":0.6639999747276306},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.9369999766349792},{"id":"https://openalex.org/keywords/neuropathy","display_name":"neuropathy","score":0.8309999704360962},{"id":"https://openalex.org/keywords/febrile-neutropenia","display_name":"febrile neutropenia","score":0.746999979019165},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.43700000643730164},{"id":"https://openalex.org/keywords/clinical-response","display_name":"clinical response","score":0.593999981880188},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9179999828338623},{"id":"https://openalex.org/keywords/her2-immunohistochemistry","display_name":"HER2 immunohistochemistry","score":0.5849999785423279},{"id":"https://openalex.org/keywords/her2-fluorescence-in-situ-hybridization","display_name":"HER2 fluorescence in situ hybridization","score":0.878000020980835}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9422250986099243},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6933807134628296},{"id":"https://openalex.org/C2780350996","wikidata":"https://www.wikidata.org/wiki/Q420532","display_name":"Vinorelbine","level":4,"score":0.6892573833465576},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.653485894203186},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.6104496121406555},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.6014621257781982},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.5461094379425049},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5277486443519592},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.44373106956481934},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.43185698986053467},{"id":"https://openalex.org/C78085059","wikidata":"https://www.wikidata.org/wiki/Q641303","display_name":"Ejection fraction","level":3,"score":0.4259951114654541},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.39248669147491455},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.37463629245758057},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3657528758049011},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.32586658000946045},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.15083980560302734},{"id":"https://openalex.org/C2778198053","wikidata":"https://www.wikidata.org/wiki/Q181754","display_name":"Heart failure","level":2,"score":0.11029660701751709}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2004.22.14_suppl.636","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.636","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.14_suppl.636","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"doi:10.1200/jco.2004.22.90140.636","doi":"https://doi.org/10.1200/jco.2004.22.90140.636","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.90140.636","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2587344325","https://openalex.org/W2249773492","https://openalex.org/W2589330019","https://openalex.org/W2044833729","https://openalex.org/W2028457403","https://openalex.org/W2130521606","https://openalex.org/W2253826697","https://openalex.org/W2045945601","https://openalex.org/W2009402447","https://openalex.org/W2598807102"],"abstract_inverted_index":{"636":[0],"Background:":[1],"Combination":[2],"therapy":[3],"of":[4,34,177,206,211,221,228,233,239,261,282,288,295,302,344],"vinorelbine":[5],"(N)":[6],"and":[7,18,70,79,103,107,123,155,182,235,298,356],"trastuzumab":[8],"(H)":[9],"has":[10,191],"recently":[11],"been":[12,194,248],"shown":[13],"to":[14,324,358],"be":[15,359],"an":[16],"active":[17,347],"safe":[19,360],"regimen":[20,197],"for":[21,93,153,158,268,304,311,350],"HER2":[22,41,353],"positive":[23,42,354],"MBC":[24,43,355],"patients":[25,127,150],"(Burstein":[26],"JCO":[27],"01,":[28],"19;2722\u20132730).":[29],"Here":[30],"we":[31],"report":[32],"results":[33,336],"a":[35,280],"multinational":[36],"phase":[37],"II":[38],"trial.":[39],"Methods:":[40],"pts":[44,90,157,263,278,297,314,351],"(IHC":[45],"3+":[46],"or":[47,62,114,245,365,368],"FISH":[48],"+":[49,340],"by":[50],"centralised":[51],"testing),":[52],"with":[53,66,208,332,352],"measurable":[54],"disease,":[55],"KPS":[56],"=":[57,169],"70%,":[58],"no":[59],"prior":[60,138,142],"H":[61,214,303,341],"N":[63,67,339],"were":[64,84,91,117,128,151,266],"treated":[65],":":[68],"30mg/m2/week":[69],"H:":[71],"4":[72,296],"mg/kg":[73],"on":[74],"day1":[75],"as":[76],"loading":[77],"dose":[78],"then":[80],"2mg/kg":[81],"/w.":[82],"Patients":[83],"reassessed":[85],"every":[86,104],"8":[87],"w.":[88],"All":[89],"evaluated":[92],"the":[94,101,131,270,345],"left":[95],"ventricular":[96],"ejection":[97],"fraction":[98],"(LVEF)":[99],"at":[100,253,275],"baseline":[102,254],"6":[105],"months":[106],"more":[108],"often":[109],"if":[110],"needed.":[111],"Either":[112],"ultrasonography":[113],"MUGA":[115],"scan":[116],"used.":[118],"Results:":[119],"Between":[120],"October":[121],"2000":[122],"June":[124],"2002,":[125],"69":[126],"included":[129],"in":[130,292],"study,":[132],"median":[133,175,183,251,271],"age:":[134],"53":[135],"years":[136],"(30\u201374),":[137],"neo/adjuvant":[139],"chemotherapy:":[140],"65.2%,":[141],"hormonal":[143],"therapy:":[144],"49.3%,":[145],"visceral":[146],"metastasis:":[147],"75.4%.":[148],"Sixty-six":[149],"evaluable":[152],"response":[154,162,178],"68":[156,262],"toxicity.":[159],"The":[160,174,196,250],"overall":[161],"rate":[163],"was":[164,172,179,186,198,255,273,290,309],"61%,":[165],"disease":[166],"control":[167],"(CR+PR+SD":[168],"24":[170],"weeks)":[171],"79%.":[173],"duration":[176],"11.7":[180],"months,":[181],"progression-free":[184],"survival":[185,190],"10":[187],"months.":[188],"Median":[189],"not":[192],"yet":[193],"reached.":[195],"well":[199],"tolerated,":[200],"WHO":[201],"grade":[202,217,223,325],"3\u20134":[203],"neutropenia":[204],"(44.6%":[205],"cy)":[207],"2":[209],"episodes":[210],"febrile":[212],"neuropenia,":[213],"infusion":[215],"reactions":[216],"3":[218,293,313,326],"(1.5":[219],"%":[220,227,232,238],"pts),":[222,229],"3:":[224],"asthenia":[225],"(8.8":[226],"neuropathy":[230],"(4":[231],"pts)":[234],"infection":[236],"(6":[237],"pts).":[240],"No":[241],"severe":[242],"nausea,":[243],"vomiting":[244],"alopecia":[246],"have":[247],"reported.":[249],"LVEF":[252,272,283,289],"64%.":[256],"At":[257],"week":[258],"28,":[259],"forty-one":[260],"(60":[264],"%)":[265],"rescreened":[267],"LVEF;":[269],"unchanged":[274],"58%.":[276],"Four":[277],"experienced":[279],"decline":[281,287],"below":[284],"50%.":[285],"This":[286],"asymptomatic":[291],"out":[294],"resolved":[299,331],"after":[300],"discontinuation":[301],"one":[305,343],"cycle.":[306],"Subsequently":[307],"treatment":[308,348],"reintroduced":[310],"these":[312],"without":[315],"further":[316],"complications.":[317],"One":[318],"pt":[319],"came":[320],"off":[321],"study":[322],"due":[323],"symptomatic":[327],"cardiac":[328],"dysfunction":[329],"that":[330,338],"therapy.":[333],"Conclusion:":[334],"Our":[335],"indicate":[337],"is":[342],"most":[346],"regimens":[349],"demonstrates":[357],"regimen.":[361],"Author":[362],"Disclosure":[363],"Employment":[364],"Leadership":[366],"Consultant":[367],"Advisory":[369],"Stock":[370],"Ownership":[371],"Honoraria":[372],"Research":[373],"Funding":[374],"Expert":[375],"Testimony":[376],"Other":[377],"Remuneration":[378],"Roche;":[379],"Aventis;":[380],"Lilly;":[381],"Pierre":[382],"Fabre":[383]},"counts_by_year":[],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2016-06-24T00:00:00"}